Trial Profile

Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ORM 5029 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Orum Therapeutics

Most Recent Events

04 Jul 2025 Status changed from active, no longer recruiting to discontinued.
15 Nov 2024 Status changed from recruiting to active, no longer recruiting.
06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com